>
Rapid Dose Therapeutics logo

DOSE - Rapid Dose Therapeutics Share Price

C$0.21 0.0  0.0%

Last Trade - 10/05/21

Sector
Healthcare
Size
Micro Cap
Market Cap £9.46m
Enterprise Value £10.3m
Revenue £112k
Position in Universe 1726th / 2705
Bullish
Bearish
Unlock DOSE Revenue
Momentum
Relative Strength (%)
1m -0.83%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -61.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 29th Feb 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.10 9.60 16.3
+300
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 November 2020, RapidDose Therapeutics Corp revenues increased from C$40K toC$130K. Net loss applicable to common stockholdersdecreased 79% to C$1.4M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Lower net loss reflectsStock-Based Compensation decrease from C$2.6M (expense) toC$0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

DOSE Revenue Unlock DOSE Revenue

Net Income

DOSE Net Income Unlock DOSE Revenue

Normalised EPS

DOSE Normalised EPS Unlock DOSE Revenue

PE Ratio Range

DOSE PE Ratio Range Unlock DOSE Revenue

Dividend Yield Range

DOSE Dividend Yield Range Unlock DOSE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
DOSE EPS Forecasts Unlock DOSE Revenue
Profile Summary

Rapid Dose Therapeutics Corp is a Canada-based pharma-technology company. The Company offers drug delivery solutions. It offers over-the-counter and pharmaceutical drug delivery solutions. QuickStrip is its processed oral film that contains the active molecule embedded in the delivery matrix. QuickStrip is designed as an oral fast-dissolving drug delivery system, which releases pharmaceuticals, micronized oils, and a host of over-the-counter medicines. RDMx mixture is its formulation that is designed as an orally administrable composition comprising a film forming agent that is used to deliver a micronized therapeutic. Its QuickStrip Energy product delivers energizing caffeine. Its QuickStrip B12 product delivers vitamin B12 to user’s system, assisting with metabolism and physical energy. Melatonin is its QuickStrip Sleep product that delivers melatonin to the user’s system.

Directors
Last Annual February 29th, 2020
Last Interim November 30th, 2020
Incorporated February 27, 2008
Public Since December 17, 2018
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Canadian Securities Exchange
Shares in Issue 77,067,435
Free Float (0.0%)
Eligible for
ISAs
SIPPs
DOSE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DOSE
Upcoming Events for DOSE
Frequently Asked Questions for Rapid Dose Therapeutics
What is the Rapid Dose Therapeutics share price?

As of 10/05/21, shares in Rapid Dose Therapeutics are trading at C$0.21, giving the company a market capitalisation of £9.46m. This share price information is delayed by 15 minutes.

How has the Rapid Dose Therapeutics share price performed this year?

Shares in Rapid Dose Therapeutics are currently trading at C$0.21 and the price has moved by -16% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Rapid Dose Therapeutics price has moved by -35.44% over the past year.

What are the analyst and broker recommendations for Rapid Dose Therapeutics?

There are no analysts currently covering Rapid Dose Therapeutics.

When will Rapid Dose Therapeutics next release its financial results?

Rapid Dose Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-11-30
What is the Rapid Dose Therapeutics dividend yield?

Rapid Dose Therapeutics does not currently pay a dividend.

Does Rapid Dose Therapeutics pay a dividend?

Rapid Dose Therapeutics does not currently pay a dividend.

When does Rapid Dose Therapeutics next pay dividends?

Rapid Dose Therapeutics does not currently pay a dividend.

How do I buy Rapid Dose Therapeutics shares?

To buy shares in Rapid Dose Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Rapid Dose Therapeutics?

Shares in Rapid Dose Therapeutics are currently trading at C$0.21, giving the company a market capitalisation of £9.46m.

Where are Rapid Dose Therapeutics shares listed? Where are Rapid Dose Therapeutics shares listed?

Here are the trading details for Rapid Dose Therapeutics:

Country of listing: Canada
Exchange: CNX
Ticker Symbol: DOSE
What kind of share is Rapid Dose Therapeutics?

Based on an overall assessment of its quality, value and momentum, Rapid Dose Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Rapid Dose Therapeutics share price forecast 2021?

Shares in Rapid Dose Therapeutics are currently priced at C$0.21. At that level they are trading at 0.757% discount to the analyst consensus target price of 0.00.

Analysts covering Rapid Dose Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of 0.01 for the next financial year.

How can I tell whether the Rapid Dose Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rapid Dose Therapeutics. Over the past six months, the relative strength of its shares against the market has been -45.19%. At the current price of C$0.21, shares in Rapid Dose Therapeutics are trading at -19.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Rapid Dose Therapeutics PE Ratio?

We were not able to find PE ratio data for Rapid Dose Therapeutics.

Who are the key directors of Rapid Dose Therapeutics?

Rapid Dose Therapeutics's management team is headed by:

Paul Ankcorn - PRE
Kees Van Winters - IND
James Patterson - IND
Harry Burgess - IND
Kristina Shea - SEC
Jason Lewis - SVP
Rishi Kapadia - CTR
Peter Hasler - DRC
Who are the major shareholders of Rapid Dose Therapeutics?

Here are the top five shareholders of Rapid Dose Therapeutics based on the size of their shareholding:

Upsdell (Mark Andrew) Individual Investor
Percentage owned: 15.48% (11.9m shares)
Lewis (Jason Daniel) Individual Investor
Percentage owned: 6.27% (4.84m shares)
Hyland (Douglas Alan) Individual Investor
Percentage owned: 1.04% (800k shares)
Nagamatsu (Miles A) Individual Investor
Percentage owned: 0.39% (300k shares)
Shea (Kristina) Individual Investor
Percentage owned: 0.25% (190k shares)
Similar to DOSE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.